Whitehawk Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
Whitehawk Therapeutics reported a cash balance of $123.0 million as of March 31, 2026, sufficient to fund operations into 2028, while Phase 1 dose-escalation trials for HWK-007 and HWK-016 remain ongoing. Management plans to submit an IND for HWK-206 in mid-2026, with initial data for the ongoing Phase 1 trials anticipated in the first half of 2027.
Key figures
- Revenue
- 0
- Revenue Yoy
- -100%
- Net loss
- 22194000
- Cash runway
- into 2028
- Rd expenses
- 17232000
- Cash position
- 123000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.